Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024


Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.

To participate, dial 800-274-8461 within the U.S. or (+1) 203-518-9814 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.


These press releases may also interest you

at 12:20
Aubex Therapeutics Launches to Revolutionize Cancer Treatment With Novel Compounds Directed Toward the Tumor Microenvironment
Aubex Therapeutics Inc., a pioneering biotechnology firm, announced its official launch, heralding a new era in the battle against cancer. Under the guidance of Board Member and Interim CEO, Jeffrey Glazer, Aubex's initial program is focused on novel...

at 12:15
Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
Affini-T Therapeutics, Inc., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T...

at 12:15
uLab® enhances digital workflow flexibility with improved clinical features and new bundle purchasing options
uLab Systems® announces the release of the uDesign® 9 treatment planning software, the AI-assisted platform designed exclusively for orthodontists to maximize their control over treatment and provide more aligner workflow flexibility than any other...

at 12:15
ImageTrend Launches Quality Improvement Tools for Fire Organizations
ImageTrend, LLC., the leader in innovative public safety and healthcare software solutions, is excited to announce the launch of its Fire Continuous Quality Improvement (CQI) module, a highly requested tool that will help fire services measure and...

at 12:09
Asthma Awareness Month: American Lung Association Focuses on Addressing Challenges of Extreme Heat and Asthma
Millions of people in the U.S. live with asthma, which is a life-long chronic lung disease. While we have proven asthma management techniques and treatments, people living with asthma and their healthcare providers face increasing challenges due to...

at 12:07
EverGlade Consulting Welcomes New Managing Director, Joe Larsen
EverGlade Consulting is pleased to announce the appointment of Dr. Joe Larsen as Managing Director, effective April 2024. Dr. Larsen brings with him a rich background in biomedical research and healthcare policy, significantly enhancing EverGlade's...

More news about Health...


News published on and distributed by: